KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
|
Entry into a Material Definitive Agreement.
|
between Acucela Inc. (Acucela), a wholly-owned subsidiary of
Kubota Pharmaceutical Holdings Co., Ltd. (the Company), and
Integrated Diagnostics, Inc. (Integrated) became effective. The
Sub-Sublease relates to the sublease by Integrated to Acucela of
approximately 8,309 square feet of rentable office space located
at 818 Stewart Street, Suite 1100, Seattle, Washington 98101 (the
Seattle Premises). The effectiveness of the Sub-Sublease and
commencement of its term was conditioned on obtaining the consent
of the 818 Stewart Street Acquisition, LLC (Landlord) and Ball
Janik, LLP (Ball Janik). The term of the Sub-Sublease expires on
October 29, 2020 (the Sub-Sublease Term).
$12,290.40 for the first year of the term, subject to increases
of approximately 5% annually on May 1st>of each
year of the Sub-Sublease Term. No rent is payable for the first
two months of the Sub-Sublease Term. In addition to the base
rent, Acucela is responsible for its pro rata share of building
operating expenses, calculated with reference to the rentable
square feet of the Seattle Premises.
sublease of the Seattle Premises to its Sublease Agreement with
Ball Janik, dated November 20, 2014 (the Sublease) and Ball
Janiks lease of the Seattle Premises to its Office Lease with
Landlord, dated July 19, 2010 (the Master Lease). The
Sub-Sublease contains customary default provisions allowing
Integrated to terminate the Sub-Sublease if Acucela fails to cure
a breach of any of its obligations within specified time periods.
Acucela may not assign the Sub-Sublease or further sublet all or
any part of the Seattle Premises without prior written consent
from Integrated, Ball Janik and Landlord.
report and incorporated herein by reference. The foregoing
description of the terms and conditions of the Sub-Sublease is
qualified in its entirety by reference to such exhibit.
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant. |
hereby incorporated by reference into this Item 2.03.
|
Item 9.01
|
Financial Statements and Exhibits
|
||
|
(d) Exhibits.
|
|||
|
Exhibit Number
|
Description
|
||
|
10.1
|
Sub-Sublease Agreement by and between Integrated
Diagnostics, Inc. and Acucela Inc. |
||
About KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596)
Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome. KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) Recent Trading Information
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. (TYO:4596) closed its last trading session up +2.00 at 737.00 with 80,300 shares trading hands.
